title: Acute and chronic antibody-mediated rejection in pediatric kidney transplantation.
abstract: Acute antibody-mediated rejection is a diagnostic challenge in renal transplantation medicine. However, it is an important diagnosis to make, since chronic antibody-mediated rejection (CAMR) is the main cause of long-term graft loss. Antibody-mediated rejection is diagnosed by detecting donor-specific antibodies (DSAs) in the blood in combination with observing typical histomorphological signs in kidney biopsy, as described in the Banff classification. Therapy is based on the removal of DSAs by administering intravenous immunoglobulins (IVIGs), plasmapheresis, or immunoadsorption. Reoccurrence of antibodies is diminished by the use of rituximab, increased immunosuppression, and in some cases additional experimental substances. A combination of these techniques has been shown to be successful in the majority of cases of acute and chronic antibody-mediated rejection. Routine DSA monitoring is warranted for early detection of antibody-mediated rejection.
authors.affiliation: Department of Pediatric Nephrology, Hannover Medical School, Carl-Neuberg-Straße 1, 30655, Hannover, Germany, larspape@t-online.de.
authors.forename: Lars
authors.initials: L
authors.lastname: Pape
authors.forename: Jan U
authors.initials: JU
authors.lastname: Becker
authors.forename: Stephan
authors.initials: S
authors.lastname: Immenschuh
authors.forename: Thurid
authors.initials: T
authors.lastname: Ahlenstiel
mesh_terms: D000208:Acute Disease; D000906:Antibodies / Q000276:immunology*; D002648:Child; D002908:Chronic Disease; D006084:Graft Rejection / Q000276:immunology* / Q000473:pathology; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D016030:Kidney Transplantation
chemical_list: D000906:Antibodies; D006680:HLA Antigens